SE0103424D0 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
SE0103424D0
SE0103424D0 SE0103424A SE0103424A SE0103424D0 SE 0103424 D0 SE0103424 D0 SE 0103424D0 SE 0103424 A SE0103424 A SE 0103424A SE 0103424 A SE0103424 A SE 0103424A SE 0103424 D0 SE0103424 D0 SE 0103424D0
Authority
SE
Sweden
Prior art keywords
drug
sub
alpha
relates
pharmaceutical formulation
Prior art date
Application number
SE0103424A
Other languages
English (en)
Swedish (sv)
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103424A priority Critical patent/SE0103424D0/xx
Publication of SE0103424D0 publication Critical patent/SE0103424D0/xx
Priority to US10/492,629 priority patent/US20060058381A1/en
Priority to PL02368226A priority patent/PL368226A1/xx
Priority to CA002462219A priority patent/CA2462219A1/en
Priority to RU2004115023/15A priority patent/RU2004115023A/ru
Priority to BR0213248-6A priority patent/BR0213248A/pt
Priority to MXPA04003520A priority patent/MXPA04003520A/es
Priority to PCT/GB2002/004621 priority patent/WO2003032950A1/en
Priority to CNA028203747A priority patent/CN1571658A/zh
Priority to JP2003535754A priority patent/JP3639587B2/ja
Priority to HU0401369A priority patent/HUP0401369A3/hu
Priority to IL16130602A priority patent/IL161306A0/xx
Priority to EP02770069A priority patent/EP1439823A1/en
Priority to ARP020103826A priority patent/AR036877A1/es
Priority to KR1020047005493A priority patent/KR20050035163A/ko
Priority to ZA200402729A priority patent/ZA200402729B/xx
Priority to NO20041485A priority patent/NO20041485L/no
Priority to IS7219A priority patent/IS7219A/is
Priority to CO04043957A priority patent/CO5580755A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0103424A 2001-10-15 2001-10-15 Pharmaceutical formulation SE0103424D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
KR1020047005493A KR20050035163A (ko) 2001-10-15 2002-10-11 (ｒ)-비칼루타미드를 포함하는 약학적 제제
CNA028203747A CN1571658A (zh) 2001-10-15 2002-10-11 包含(r)－比卡鲁胺的药物制剂
HU0401369A HUP0401369A3 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
CA002462219A CA2462219A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide
RU2004115023/15A RU2004115023A (ru) 2001-10-15 2002-10-11 Фапмацевтическая композиция, содержащая (r)-бикалутамид
BR0213248-6A BR0213248A (pt) 2001-10-15 2002-10-11 Formulação farmacêutica, dose farmacêutica, dispersão sólida de um polìmero entérico, métodos para o tratamento de cãncer de próstata e/ou para a redução do risco de cancer de próstata em um paciente, para aumentara biodisponibilidade e a estabilidade em armazenamento de 4'-ciano-alfa',alfa',alfa' -trifluoro-3-(4-fluorofenilsilfonil)-2-hidróxi-2-metil propiono-m-toluidida, e para a preparação de uma formulação farmacêutica, e, usos de 4'-ciano-alfa',alfa',alfa'-trifluoro-3-(4-fluorofenilsu lfonil -2-hidróxi-2-metilpropiono-m-toluidida e de um polìmero entérico
MXPA04003520A MXPA04003520A (es) 2001-10-15 2002-10-11 Formulacion farmaceutica que comprende (r)-bicalutamida.
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide
US10/492,629 US20060058381A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalitamide
JP2003535754A JP3639587B2 (ja) 2001-10-15 2002-10-11 医薬製剤
PL02368226A PL368226A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide
IL16130602A IL161306A0 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalutamide
EP02770069A EP1439823A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r)-bicalutamide
ARP020103826A AR036877A1 (es) 2001-10-15 2002-10-11 Formulacion farmaceutica
ZA200402729A ZA200402729B (en) 2001-10-15 2004-04-07 Pharmaceutical formulation comprising (R) -bicalutamide.
NO20041485A NO20041485L (no) 2001-10-15 2004-04-13 Farmasoytisk formulering omfattende (R)-bicalutamid
IS7219A IS7219A (is) 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð
CO04043957A CO5580755A2 (es) 2001-10-15 2004-05-12 Formulacion farmaceutica comprendiendo (r)-bicalutamida

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0103424D0 true SE0103424D0 (sv) 2001-10-15

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation

Country Status (19)

Country Link
US (1) US20060058381A1 (xx)
EP (1) EP1439823A1 (xx)
JP (1) JP3639587B2 (xx)
KR (1) KR20050035163A (xx)
CN (1) CN1571658A (xx)
AR (1) AR036877A1 (xx)
BR (1) BR0213248A (xx)
CA (1) CA2462219A1 (xx)
CO (1) CO5580755A2 (xx)
HU (1) HUP0401369A3 (xx)
IL (1) IL161306A0 (xx)
IS (1) IS7219A (xx)
MX (1) MXPA04003520A (xx)
NO (1) NO20041485L (xx)
PL (1) PL368226A1 (xx)
RU (1) RU2004115023A (xx)
SE (1) SE0103424D0 (xx)
WO (1) WO2003032950A1 (xx)
ZA (1) ZA200402729B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1503662A (zh) * 2001-02-27 2004-06-09 药物制剂
ES2332920T3 (es) 2004-01-20 2010-02-15 Novartis Ag Proceso y formulacion de compresion directa.
US20080161404A1 (en) * 2005-02-23 2008-07-03 Astrazeneca Ab Bicalutamide for Delivering Increasing Steady State Plasma Levels
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP2012516900A (ja) 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
RU2016104643A (ru) 2013-08-12 2017-09-19 Токай Фармасьютикалз, Инк. Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
ES2883187T3 (es) 2014-12-05 2021-12-07 Aragon Pharmaceuticals Inc Composiciones anticancerosas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
ATE159426T1 (de) * 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
JPH09508125A (ja) * 1994-01-21 1997-08-19 セプラコー，インコーポレイテッド 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
CN1503662A (zh) * 2001-02-27 2004-06-09 药物制剂
MXPA03008999A (es) * 2001-04-02 2004-02-12 Astrazeneca Ab Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.

Also Published As

Publication number Publication date
IS7219A (is) 2004-04-14
US20060058381A1 (en) 2006-03-16
WO2003032950A1 (en) 2003-04-24
EP1439823A1 (en) 2004-07-28
CO5580755A2 (es) 2005-11-30
CA2462219A1 (en) 2003-04-24
ZA200402729B (en) 2005-01-13
AR036877A1 (es) 2004-10-13
IL161306A0 (en) 2004-09-27
JP2004521963A (ja) 2004-07-22
CN1571658A (zh) 2005-01-26
BR0213248A (pt) 2004-09-28
NO20041485L (no) 2004-04-13
KR20050035163A (ko) 2005-04-15
PL368226A1 (en) 2005-03-21
RU2004115023A (ru) 2005-04-10
JP3639587B2 (ja) 2005-04-20
HUP0401369A2 (hu) 2004-11-29
MXPA04003520A (es) 2004-07-23
HUP0401369A3 (en) 2006-05-29

Similar Documents

Publication Publication Date Title
EE200300476A (et) 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
WO2002067893A3 (en) Pharmaceutical formulation comprising bicalutamide
SE0103424D0 (sv) Pharmaceutical formulation
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
BRPI0113757B8 (pt) derivados de quinolinona como inibidores de tirosina quinase
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BR0208373A (pt) Inibidores da tirosina cinase
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
IS6329A (is) Lyf til að meðhöndla illkynja æxli
DE60229046D1 (de) Chinazolin derivate
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
NO20023486D0 (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
BR0017120A (pt) Composição farmacêutica
SE0102440D0 (sv) New compound
SE0103839D0 (sv) Pharmaceutical formulation & product
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
SE9902267D0 (sv) New compounds
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen